Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways

Kasorn,Anongnard; Loison,Fabien; Kangsamaksin,Thaned; Jongrungruangchok,Suchada; Ponglikitmongkol,Mathurose

doi:10.3892/or.2018.6189

Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways

Authors:
- Anongnard Kasorn
- Fabien Loison
- Thaned Kangsamaksin
- Suchada Jongrungruangchok
- Mathurose Ponglikitmongkol
View Affiliations

Affiliations: Department of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand, Department of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, Department of Pharmaceutical Chemistry, Rangsit University, Pathum Thani 12000, Thailand
Published online on: January 4, 2018 https://doi.org/10.3892/or.2018.6189
Pages: 1378-1386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common cancer in women worldwide. Progression and aggressiveness of breast cancer is usually associated with its migration and invasion abilities. Recently, natural products with potential anticancer activity have become attractive candidates for alternative treatment of cancer. A fungal metabolite, terrein, isolated from the Aspergillus terreus has been revealed to exhibit selective anticancer activity; although this molecule has a variety of biological activities. The inhibitory effect on cell proliferation in hepatoma, keratinocytes, and lung cancer cells was due to cell cycle arrest without induction of apoptosis. In contrast, its effects on cervical and breast cancer cells were mediated through activation of the apoptotic process. However, the effect of terrein on cell migration and invasion has not been explored. In the present study we analyzed the molecular effects of terrein on cell adhesion, cell migration, and cell invasion using two breast cancer cell lines, MCF-7 and MDA-MB-231, which exhibit different levels of invasiveness. Terrein induced apoptosis in both breast cancer cell lines in a dose-dependent manner. In addition, at a non-toxic concentration terrein exhibited a weak inhibition of cell adhesion, using either fibronectin or type IV collagen as substrates. Notably, terrein significantly inhibited both the migration and invasion abilities of MDA-MB-231 cells at the same non-toxic concentration. A marked decrease in MMP-2 and MMP-9 transcripts, as evaluated by real-time PCR, confirmed the anti-invasion effect of terrein at the transcriptional level. Western blot analyses revealed that terrein treatment suppressed RhoB expression and reduced Rac1 phosphorylation, leading to Rho GTPase inhibition. In addition, terrein-treated MCF-7 and MDA-MB-231 cells both displayed a scattered pattern of migration, suggesting that the suppression of RhoB and Rac1 disturbed the collective migration processes of breast cancer cells.

View Figures

View References

1	Torre LA, Islami F, Siegel RL, Ward EM and Jemal A: Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
2	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
4	Lee S, Kim WG, Kim E, Ryoo IJ, Lee HK, Kim JN, Jung SH and Yoo ID: Synthesis and melanin biosynthesis inhibitory activity of (+/-)-terrein produced by Penicillium sp. 20135. Bioorg Med Chem Lett. 15:471–473. 2005. View Article : Google Scholar : PubMed/NCBI
5	Malmstrøm J, Christophersen C, Barrero AF, Oltra JE, Justicia J and Rosales A: Bioactive metabolites from a marine-derived strain of the fungus Emericella variecolor. J Nat Prod. 65:364–367. 2002. View Article : Google Scholar : PubMed/NCBI
6	Phattanawasin P, Pojchanakom K, Sotanaphun U, Piyapolrungroj N and Zungsontiporn S: Weed growth inhibitors from Aspergillus fischeri TISTR 3272. Nat Prod Res. 21:1286–1291. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kim D-S, Lee H-K, Park S-H, Lee S, Ryoo IJ, Kim WG, Yoo ID, Na JI, Kwon SB and Park KC: Terrein inhibits keratinocyte proliferation via ERK inactivation and G2/M cell cycle arrest. Exp Dermatol. 17:312–317. 2008. View Article : Google Scholar : PubMed/NCBI
8	Zhang F, Mijiti M, Ding W, Song J, Yin Y, Sun W and Li Z: (+)-Terrein inhibits human hepatoma Bel 7402 proliferation through cell cycle arrest. Oncol Rep. 33:1191–1200. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chen YF, Wang SY, Shen H, Yao XF, Zhang FL and Lai D: The marine-derived fungal metabolite, terrein, inhibits cell proliferation and induces cell cycle arrest in human ovarian cancer cells. Int J Mol Med. 34:1591–1598. 2014. View Article : Google Scholar : PubMed/NCBI
10	Liao WY, Shen CN, Lin LH, Yang YL, Han HY, Chen JW, Kuo SC, Wu SH and Liaw CC: Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic Aspergillus terreus. J Nat Prod. 75:630–635. 2012. View Article : Google Scholar : PubMed/NCBI
11	Porameesanaporn Y, Uthaisang-Tanechpongtamb W, Jarintanan F, Jongrungruangchok S and Thanomsub Wongsatayanon B: Terrein induces apoptosis in HeLa human cervical carcinoma cells through p53 and ERK regulation. Oncol Rep. 29:1600–1608. 2013. View Article : Google Scholar : PubMed/NCBI
12	Shibata A, Ibaragi S, Mandai H, Tsumura T, Kishimoto K, Okui T, Hassan NM, Shimo T, Omori K, Hu GF, et al: Synthetic terrein inhibits progression of head and neck cancer by suppressing angiogenin production. Anticancer Res. 36:2161–2168. 2016.PubMed/NCBI
13	Cairns RA, Khokha R and Hill RP: Molecular mechanisms of tumor invasion and metastasis: An integrated view. Curr Mol Med. 3:659–671. 2003. View Article : Google Scholar : PubMed/NCBI
14	Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res. 51 Suppl 18:5054s–5059s. 1991.PubMed/NCBI
15	Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
16	Ridley AJ: Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16:522–529. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ridley AJ: Rho GTPase signalling in cell migration. Curr Opin Cell Biol. 36:103–112. 2015. View Article : Google Scholar : PubMed/NCBI
18	Ridley AJ: Rho family proteins: Coordinating cell responses. Trends Cell Biol. 11:471–477. 2001. View Article : Google Scholar : PubMed/NCBI
19	Vega FM and Ridley AJ: The RhoB small GTPase in physiology and disease. Small GTPases. Nov 22–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
20	Bravo-Cordero JJ, Moshfegh Y, Condeelis J and Hodgson L: Live cell imaging of RhoGTPase biosensors in tumor cells. Methods Mol Biol. 1046:359–370. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhuge Y and Xu J: Rac1 mediates type I collagen-dependent MMP-2 activation. Role in cell invasion across collagen barrier. J Biol Chem. 276:16248–16256. 2001. View Article : Google Scholar : PubMed/NCBI
22	Gebäck T, Schulz MM, Koumoutsakos P and Detmar M: TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 46:265–274. 2009.PubMed/NCBI
23	Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, Takahashi O, Miyamoto M, Hamada J, Moriuchi T, et al: Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 146:32–42. 2008. View Article : Google Scholar : PubMed/NCBI
24	Wanichwatanadecha P, Sirisrimangkorn S, Kaewprag J and Ponglikitmongkol M: Transactivation activity of human papillomavirus type 16 E6*I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells. J Gen Virol. 93:1081–1092. 2012. View Article : Google Scholar : PubMed/NCBI
25	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
26	Koujan SE, Gargarib BP, Pirouzpanah S and Khalili M: Matrix metalloproteinases and breast cancer. Thrita. 4:e219592015.
27	Prudnikova TY, Rawat SJ and Chernoff J: Molecular pathways: Targeting the kinase effectors of RHO-family GTPases. Clin Cancer Res. 21:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
28	Cherigo L, Lopez D and Martinez-Luis S: Marine natural products as breast cancer resistance protein inhibitors. Mar Drugs. 13:2010–2029. 2015. View Article : Google Scholar : PubMed/NCBI
29	Demasi M, Felicio A, Pacheco A, Leite H, Limaa C and Andrade L: Studies on terrein as a new class of proteasome inhibitors. J Braz Chem Soc. 21:299–305. 2010. View Article : Google Scholar
30	Adams J and Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22:304–311. 2004. View Article : Google Scholar : PubMed/NCBI
31	Mandai H, Omori K, Yamamoto D, Tsumura T, Murota K, Yamamoto S, Mitsudo K, Ibaragi S, Sasaki A, Maeda H, et al: Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. Bioorg Med Chem. 22:5338–5344. 2014. View Article : Google Scholar : PubMed/NCBI
32	Lee YH, Lee SJ, Jung JE, Kim JS, Lee NH and Yi HK: Terrein reduces age-related inflammation induced by oxidative stress through Nrf2/ERK1/2/HO-1 signalling in aged HDF cells. Cell Biochem Funct. 33:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
33	Cirit M, Grant KG and Haugh JM: Systemic perturbation of the ERK signaling pathway by the proteasome inhibitor, MG132. PLoS One. 7:e509752012. View Article : Google Scholar : PubMed/NCBI
34	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
35	Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999. View Article : Google Scholar : PubMed/NCBI
36	Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR and Symons M: Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene. 24:7821–7829. 2005. View Article : Google Scholar : PubMed/NCBI
37	Gadea G, Sanz-Moreno V, Self A, Godi A and Marshall CJ: DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol. 18:1456–1465. 2008. View Article : Google Scholar : PubMed/NCBI
38	Nassar N, Cancelas J, Zheng J, Williams DA and Zheng Y: Structure-function based design of small molecule inhibitors targeting Rho family GTPases. Curr Top Med Chem. 6:1109–1116. 2006. View Article : Google Scholar : PubMed/NCBI
39	Akbar H, Cancelas J, Williams DA, Zheng J and Zheng Y: Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol. 406:554–565. 2006. View Article : Google Scholar : PubMed/NCBI
40	Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP and Dharmawardhane S: Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem. 287:13228–13238. 2012. View Article : Google Scholar : PubMed/NCBI
41	Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
42	Brown GT and Murray GI: Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 237:273–281. 2015. View Article : Google Scholar : PubMed/NCBI
43	Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP and Karamanos NK: Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 104:155–160. 2003. View Article : Google Scholar : PubMed/NCBI
44	Farabegoli F, Govoni M, Spisni E and Papi A: EGFR inhibition by (−)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion. Biosci Rep. 37:BSR201701682017. View Article : Google Scholar : PubMed/NCBI
45	Lou C, Zhu Z, Zhao Y, Zhu R and Zhao H: Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/-9 and heparanase in MDA-MB-231 cells. Oncol Rep. 37:179–184. 2017. View Article : Google Scholar : PubMed/NCBI
46	Bakar F, Kilic-Kurt Z, Caglayan MG and Olgen S: The effects of 1,3,5-trisubstituted indole derivatives on cell growth, apoptosis and MMP-2/9 mRNA expression of MCF-7 human breast cancer cells. Anticancer Agents Med Chem. 17:762–767. 2017. View Article : Google Scholar : PubMed/NCBI
47	Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S and Iwamoto Y: Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res. 92:429–438. 2001. View Article : Google Scholar : PubMed/NCBI
48	Aiuti A, Webb IJ, Bleul C, Springer T and Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34⁺ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34⁺ progenitors to peripheral blood. J Exp Med. 185:111–120. 1997. View Article : Google Scholar : PubMed/NCBI
49	Bartolomé RA, Molina-Ortiz I, Samaniego R, Sánchez-Mateos P, Bustelo XR and Teixidó J: Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res. 66:248–258. 2006. View Article : Google Scholar : PubMed/NCBI